Naveen Ramalingam, PhD, is responsible for development of microfluidics based products for both genomics and single cell applications. He has 15 years of experience in product development, systems integration, and validation at Standard BioTools. Previously he worked at National Cancer Centre Singapore on a project to develop a microfluidic nanochip for risk prediction of human hepatocellular carcinoma recurrence. Dr. Ramalingam is an active member of the American Association for Cancer Research (AACR), Associate member of Regulatory Affairs Professionals Society (RAPS), member of the American Association of Immunologists (AAI), member of the Association of Molecular Pathology (AMP) and American Association for Clinical Chemistry (AACC). He is on the editorial board member for Global Drugs and Therapeutics (GDT) journal and Annals of Nanoscience and Nanotechnology. He has written 24 peer reviewed research publications, three book chapters, and 19 conference presentations.
Revolutionizing Pharmacogenomics: qPCRpowered Simultaneous SNP, CNV, and Fragment Profiling
Traditional qPCR and CEbased methods use separate cumbersome workflows for SNP genotyping, CNV and fragment length determination. In this talk, we introduce a single workflow to simultaneously profile SNPs, CNVs, and fragment length pharmacogenomic targets using buccal swabs without extraction on a nanofluidic qPCRbased system.
Standard BioTools™, previously known as Fluidigm®, is driven by a bold vision – Unleashing tools to accelerate breakthroughs in human health.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 PGx Showcase will provide 15 minute speaking opportunities for selected companies working with the latest technologies in precision medicine to highlight their contributions to the field.